Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D, Inc.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient with eosinophilic asthma who completed the treatment period of a double-blind, placebo controlled sc reslizumab study (Study C38072-AS-30025 or C38072-AS-30027)
\~\~ Additional criteria apply, please contact the investigator for more information
You may not be if
Patient has received any reslizumab administration in any previous clinical trial other than Studies C38072-AS-30025 and C38072-AS-30027.
The patient has any clinically significant, uncontrolled medical condition
The patient has another confounding underlying lung disorder
The patient has a known/diagnosed hypereosinophilic syndrome.
The patient has a diagnosis of malignancy within 5 years of the screening visit, except for treated and cured non-melanoma skin cancers.
The patient is a pregnant or lactating woman
The patient is a current smoker (ie, has smoked within the last 6 months before screening) or has a smoking history ≥10 pack-years.
The patient is currently using any systemic immunosuppressive or immunomodulatory agents other than OCS
The patient has a history of allergic reaction or hypersensitivity to any component of the study drug.
The patient has a history of an immunodeficiency disorder including human immunodeficiency virus (HIV).
* Additional criteria apply, please contact the investigator for more information
Clareo Health | A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
